Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Pancreatic Neoplasms 6Neoplasms 6Prostatic Neoplasms 5Ovarian Neoplasms 5Leukemia, Myeloid, Acute 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Leukemia 4Colorectal Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Radiodermatitis 2Neoplasms by Site 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Communication 2Carcinoma, Transitional Cell 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1

Interventions

vofatamab 2B701 protein, Human herpesvirus 6 2valrubicin 1pembrolizumab 1Standard of Care 1Mitomycin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urologic Diseases × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡